Vaccines are critical tools in controlling infectious diseases, yet traditional production methods face significant challenges, including high costs, complex infrastructure requirements, and reliance on cold-chain logistics. These limitations restrict vaccine access, especially in low-resource regions, and were starkly exposed during the COVID-19 pandemic, underscoring the need for innovative vaccine platforms. Plant-derived vaccines, in which antigenic proteins are produced in plants using recombinant DNA technology, represent a promising alternative.
No takes yet. Share an insight, caveat, or question.
Diao et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: